Perrigo CEO Joseph Papa Sees No Easy Path for Mylan to Acquire His Company

In first comments on takeover attempt since Teva Pharmaceuticals dropped its pursuit of Mylan, Papa reiterates that the $205 per share offer substantially undervalues Perrigo.

comments Print
REUTERS - Perrigo, the U.S. drug maker traded on the Tel Aviv Stock Exchange, on Wednesday made a fresh case for rejecting a $34 billion offer from generic drugmaker Mylan, saying Mylan’s recent share price...